

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

(Print or Type Responses)

| | | | | |
|--|---|---|--|--|
| 1. Name and Address of Reporting Person* Patel Snehal (Last) (First) (Middle) C/O GREENWICH LIFESCIENCES, INC., 3992 BLUEBONNET DR, BUILDING 14 (Street) STAFFORD, TX 77477 (City) (State) (Zip) | 2. Date of Event Requiring Statement (Month/Day/Year) 09/24/2020 | 3. Issuer Name and Ticker or Trading Symbol Greenwich LifeSciences, Inc. [GLSI] | | |
| | | 4. Relationship of Reporting Person(s) to Issuer (Check all applicable) <input checked="" type="checkbox"/> Director <input type="checkbox"/> 10% Owner <input checked="" type="checkbox"/> Officer (give title below) <input type="checkbox"/> Other (specify below) CHIEF EXECUTIVE OFFICER | | 5. If Amendment, Date Original Filed(Month/Day/Year) |
| | | 6. Individual or Joint/Group Filing(Check Applicable Line) <input checked="" type="checkbox"/> Form filed by One Reporting Person <input type="checkbox"/> Form filed by More than One Reporting Person | | |

Table I - Non-Derivative Securities Beneficially Owned

| 1. Title of Security (Instr. 4) | 2. Amount of Securities Beneficially Owned (Instr. 4) | 3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5) | 4. Nature of Indirect Beneficial Ownership (Instr. 5) |
|---------------------------------|---|--|---|
| Common stock | 749,336 ⁽¹⁾ | D | |
| Common stock | 176,798 | I | See footnote ⁽²⁾ |
| Common stock | 2,405,670 | I | See footnote ⁽³⁾ |
| Common stock | 1,320,226 | I | See footnote ⁽⁴⁾ |
| Common stock | 1,329,590 | I | See footnote ⁽⁵⁾ |

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

SEC 1473 (7-02)

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

| 1. Title of Derivative Security (Instr. 4) | 2. Date Exercisable and Expiration Date (Month/Day/Year) | | 3. Title and Amount of Securities Underlying Derivative Security (Instr. 4) | | 4. Conversion or Exercise Price of Derivative Security | 5. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 5) | 6. Nature of Indirect Beneficial Ownership (Instr. 5) |
|--|--|-----------------|---|----------------------------|--|---|---|
| | Date Exercisable | Expiration Date | Title | Amount or Number of Shares | | | |
| Series A Preferred Stock | ⁽⁶⁾ | ⁽⁶⁾ | Common stock | 176,448 | \$ ⁽¹⁰⁾ | D | |
| Series A Preferred Stock | ⁽⁶⁾ | ⁽⁶⁾ | Common stock | 1,144,529 | \$ ⁽¹⁰⁾ | I | See footnote ⁽²⁾ |
| Series B Preferred Stock | ⁽⁷⁾ | ⁽⁷⁾ | Common stock | 13,736 | \$ ⁽¹¹⁾ | D | |
| Series B Preferred Stock | ⁽⁷⁾ | ⁽⁷⁾ | Common stock | 76,780 | \$ ⁽¹¹⁾ | I | See footnote ⁽¹⁴⁾ |
| Series B Preferred Stock | ⁽⁷⁾ | ⁽⁷⁾ | Common stock | 2,997 | \$ ⁽¹¹⁾ | I | See footnote ⁽²⁾ |
| Series C Preferred Stock | ⁽⁸⁾ | ⁽⁸⁾ | Common stock | 10,394 | \$ ⁽¹²⁾ | D | |
| Series C Preferred Stock | ⁽⁸⁾ | ⁽⁸⁾ | Common stock | 33,708 | \$ ⁽¹²⁾ | I | See footnote ⁽²⁾ |
| Series D Preferred Stock | ⁽⁹⁾ | ⁽⁹⁾ | Common stock | 89,510 | \$ ⁽¹³⁾ | D | |
| Series D Preferred Stock | ⁽⁹⁾ | ⁽⁹⁾ | Common stock | 45,328 | \$ ⁽¹³⁾ | I | See footnote ⁽¹⁴⁾ |
| Series D Preferred Stock | ⁽⁹⁾ | ⁽⁹⁾ | Common stock | 43,072 | \$ ⁽¹³⁾ | I | See footnote ⁽²⁾ |

Reporting Owners

| Reporting Owner Name / Address | Relationships | | | |
|---|---------------|-----------|-------------------------|-------|
| | Director | 10% Owner | Officer | Other |
| Patel Snehal C/O GREENWICH LIFESCIENCES, INC. 3992 BLUEBONNET DR, BUILDING 14 STAFFORD, TX 77477 | X | | CHIEF EXECUTIVE OFFICER | |

Signatures

| | | |
|---------------------------------|--|------------|
| /s/ Snehal Patel | | 09/24/2020 |
| **Signature of Reporting Person | | Date |

Explanation of Responses:

* If the form is filed by more than one reporting person, *see* Instruction 5(b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations. *See* 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

(1) Includes a grant of 749,064 shares of the Issuer's common stock that vests as follows: 93,633 shares of common stock vested immediately upon grant, and the balance, or 655,431 shares of common stock vests in 36 equal installments on the 1st of every month with the first installment vesting on October 1, 2019.

(2) The securities are owned by Snehal Patel IRA. Snehal Patel is the Trustee of Snehal Patel IRA, and in such capacity is deemed to hold voting and dispositive power over the securities held by such IRA.

(3) The securities are owned by Patel Family Trust 1. Snehal Patel, as co-Trustee of Patel Family Trust 1, shares voting and dispositive power over the securities held by such trust with his spouse.

(4) The securities are owned by Patel Family Trust 2. Snehal Patel, as co-Trustee of Patel Family Trust 2, shares voting and dispositive power over the securities held by such trust with his spouse.

(5) The securities are owned by Patel Family Trust 3. Snehal Patel, as co-Trustee of Patel Family Trust 3, shares voting and dispositive power over the securities held by such trust with his spouse.

The Series A Preferred Stock have no expiration date and are convertible, at the option of the holder, into shares of common stock of the Issuer at the then-effective conversion rate for no additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Issuer's Amended and

(6) Restated Certificate of Incorporation (as amended, the "Certificate of Incorporation"). The shares of Series A Preferred Stock will automatically convert into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the closing of the Issuer's initial public offering.

The Series B Preferred Stock have no expiration date and are convertible, at the option of the holder, into shares of common stock of the Issuer at the then-effective conversion rate for no additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Certificate of

(7) Incorporation). The shares of Series B Preferred Stock will automatically convert into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the closing of the Issuer's initial public offering.

The Series C Preferred Stock have no expiration date and are convertible, at the option of the holder, into shares of common stock of the Issuer at the then-effective conversion rate for no additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Certificate of

(8) Incorporation). The shares of Series C Preferred Stock will automatically convert into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the closing of the Issuer's initial public offering.

The Series D Preferred Stock have no expiration date and are convertible, at the option of the holder, into shares of common stock of the Issuer at the then-effective conversion rate for no additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Certificate of

(9) Incorporation). The shares of Series D Preferred Stock will automatically convert into shares of the Issuer's common stock at the then-effective conversion rate for no additional consideration (subject to the payment of cash, if applicable, in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the closing of the Issuer's initial public offering.

(10) The Series A Preferred Stock is convertible into shares of the Issuer's common stock at a 1-for-1 conversion rate.

(11) The Series B Preferred Stock is convertible into shares of the Issuer's common stock at a 1-for-1 conversion rate.

(12) The Series C Preferred Stock is convertible into shares of the Issuer's common stock at a 1-for-1 conversion rate.

(13) The Series D Preferred Stock is convertible into shares of the Issuer's common stock at a 1-for-1 conversion rate.

(14) Kinnary Patel is the spouse of Snehal Patel and Trustee of the Kinnary Patel IRA.

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, *See* Instruction 6 for procedure.

Potential persons who are to respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB number.